Drugs / GCSF
GCSF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02465801 Comparator | Dec 2014 → Dec 2015 | neutropenia | Tianjin SinoBiotech Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GCSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02465801 ↗ |
| Known as | Recombinant Human Granulocyte Colony-Stimulating Factor Injection | “Recombinant Human Granulocyte Colony-Stimulating Factor Injection (5μg/kg/day) will be injected subcutaneously” NCT02465801 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Granulocyte Colony-Stimulating Factor Injection” NCT02465801 ↗ |
| Route | Subcutaneous | “will be injected subcutaneously at night o'clock a.m. from the 3rd of per chemotherapy cycle” NCT02465801 ↗ |